Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer for Strategic Growth

Jazz Pharmaceuticals Welcomes Thomas Riga as Chief Business Officer Amid Strategic Growth Plans

Jazz Pharmaceuticals plc announces the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. With over 25 years of experience in the pharmaceutical sector, Riga steps into this pivotal role following his tenure as Chief Operating and Commercial Officer at Chimerix Inc. His leadership was instrumental in Chimerix's corporate strategy, particularly during its sale to Jazz in April 2025, as well as in navigating the regulatory landscape to secure U.S. approval and launch for the innovative therapy targeting H3K27M-mutant diffuse midline glioma, a rare brain tumor impacting approximately 2,000 children and young adults annually.

Riga's extensive background in business development, including the completion of over $2 billion in deals in the last five years, positions him as a key player in Jazz's future growth. As Chief Business Officer, he will spearhead corporate development initiatives and cultivate strategic partnerships that align with Jazz's mission of creating transformative medicines. His prior successes not only underscore his ability to drive revenue but also highlight his commitment to advancing treatment options for underserved patient populations, particularly in the field of oncology.

Renee Gala, President and CEO of Jazz Pharmaceuticals, commends Riga's leadership and dedication to patient care. She cites his significant contributions to the approval of Modeyso™ (dordaviprone), a treatment for an aggressive, ultra-rare brain tumor, emphasizing the company's focus on addressing pressing medical needs. Riga expresses his enthusiasm for the new role, underscoring his goal of leveraging Jazz's expertise to enhance shareholder value while delivering solutions that improve the lives of patients and their families.

In addition to Riga's appointment, Jazz Pharmaceuticals continues to prioritize its commitment to innovation and strategic growth. The company is dedicated to developing medicines that not only meet vital medical needs but also resonate with the values of patients and healthcare professionals alike. As Jazz Pharmaceuticals embarks on this new chapter, the integration of Riga’s expertise is anticipated to bolster the company’s strategic initiatives and reinforce its position in the biopharmaceutical landscape.